NCT07131449View on ClinicalTrials.gov

Serum Histone Succinylation as a Novel Prognostic Biomarker in Hematological Malignancies

Not yet recruitingOBSERVATIONAL
Enrollment

200

Participants

Timeline

Start Date

September 1, 2025

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2027

Conditions
LeukemiaLymphoma
Interventions
OTHER

This is observational studies, participants are not assigned an intervention as part of the study.

This is observational studies, participants are not assigned an intervention as part of the study.

All Listed Sponsors
lead

The First Affiliated Hospital of Xinxiang Medical College

OTHER

NCT07131449 - Serum Histone Succinylation as a Novel Prognostic Biomarker in Hematological Malignancies | Biotech Hunter | Biotech Hunter